Evidence map›Paper›PMID 37126482›Full record

ArticleAnalytical chemistry2023

Bioorthogonal Chemical Labeling Probes Targeting Sialic Acid Isomers for

Xiaowei Lu, Colin T McDowell, Calvin R K Blaschke, Liping Liu, Grace Grimsley, Luke Wisniewski, ChongFeng Gao, Anand S Mehta, Brian B Haab, Peggi M Angel and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Analytical chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. HScience advances · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Xiaowei LuDepartment of Cellular and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, South Carolina 29425-2503, United States.
Colin T McDowellDepartment of Cellular and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, South Carolina 29425-2503, United States.ORCID 0000-0001-8739-277X
Calvin R K BlaschkeDepartment of Cellular and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, South Carolina 29425-2503, United States.ORCID 0000-0003-3988-6817
Liping LiuDepartment of Cellular and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, South Carolina 29425-2503, United States.
Grace GrimsleyDepartment of Cellular and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, South Carolina 29425-2503, United States.
Luke WisniewskiDepartment of Cell Biology, Van Andel Institute, Grand Rapids, Michigan 49503, United States.
ChongFeng GaoDepartment of Cell Biology, Van Andel Institute, Grand Rapids, Michigan 49503, United States.
Anand S MehtaDepartment of Cellular and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, South Carolina 29425-2503, United States.ORCID 0000-0002-9846-9389
Brian B HaabDepartment of Cell Biology, Van Andel Institute, Grand Rapids, Michigan 49503, United States.ORCID 0000-0002-3471-1535
Peggi M AngelDepartment of Cellular and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, South Carolina 29425-2503, United States.ORCID 0000-0002-4436-555X
Richard R DrakeDepartment of Cellular and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, South Carolina 29425-2503, United States.ORCID 0000-0002-6285-6440
Medical University of South Carolina · USVan Andel Institute · US

Funding

Translational Science Laboratory Shared ResourceP30CA138313 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI John J Lemasters · 2009 to 2026
$42.7M
Proteomics CoreP30DK123704 · NIDDK · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Garth R Swanson · 2020 to 2026
$8.8M
Cellular, Biochemical and Molecular Sciences Training Program: Developing the skills and expertise needed for a changing biomedical landscapeT32GM132055 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Amy D Bradshaw, John P O'Bryan · 2019 to 2026
$3.9M
Subpopulations of Pancreatic Cancer Cells Defined by Glycan MarkersU01CA226158 · NCI · VAN ANDEL RESEARCH INSTITUTE · PI BRAND, RANDALL, HAAB, BRIAN B. · 2019 to 2023
$3.2M
Targeted Isolation and Identification of Sialylated Glycoproteins in Cancer Tissues, Cells and BiofluidsR33CA267226 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI DRAKE, RICHARD R. · 2022 to 2024
$988k
Simplified Glycan Profiling Workflows of Captured Immune Glycoproteins and CellsU01CA242096 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ANGEL, PEGGI M, DRAKE, RICHARD R. · 2019 to 2021
$818k
Development of the GlycoFibrotyper for detection of liver fibrosisR41DK124058 · NIDDK · GLYCOPATH, INC · PI MEHTA, ANAND S., SCOTT, DANIELLE · 2019 to 2019
$223k
NCI NIH HHS P30 CA138313NCI NIH HHS R33 CA267226NCI NIH HHS U01 CA226158NCI NIH HHS U01 CA242096NIDDK NIH HHS P30 DK123704NIDDK NIH HHS R41 DK124058NIGMS NIH HHS T32 GM132055
6 · The paper itself

Abstract

Sialic acid isomers attached in either α2,3 or α2,6 linkage to glycan termini confer distinct chemical, biological, and pathological properties, but they cannot be distinguished by mass differences in traditional mass spectrometry experiments. Multiple derivatization strategies have been developed to stabilize and facilitate the analysis of sialic acid isomers and their glycoconjugate carriers by high-performance liquid chromatography, capillary electrophoresis, and mass spectrometry workflows. Herein, a set of novel derivatization schemes are described that result in the introduction of bioorthogonal click chemistry alkyne or azide groups into α2,3- and α2,8-linked sialic acids. These chemical modifications were validated and structurally characterized using model isomeric sialic acid conjugates and model protein carriers. Use of an alkyne-amine, propargylamine, as the second amidation reagent effectively introduces an alkyne functional group into α2,3-linked sialic acid glycoproteins. In tissues, serum, and cultured cells, this allows for the detection and visualization of

Indexed as

Spectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationCell Line, TumorHumansPolysaccharidesSialic AcidsPolysaccharidesSialic Acids

Identifiers

PMID37126482
PMCPMC10193362
OpenAlexW4367601687

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.